Titre du document / Document title

Pioglitazone acutely influences glucose-sensitive insulin secretion in normal and diabetic human islets

Auteur(s) / Author(s)

FAN ZHANG ; SJÖHOLM Ake ; QIMIN ZHANG ;

Résumé / Abstract

We have studied acute effects of the PPARy agonist pioglitazone in vitro on human islets from both non-diabetic and type 2 diabetic subjects. In 5 mM glucose, pioglitazone caused a transient increase in insulin secretion in non-diabetic, but not diabetic, islets. Continuous presence of the drug suppressed insulin release in both non-diabetic and diabetic islets. In islets from non-diabetic subjects, both high glucose and tolbutamide-stimulated insulin secretion was inhibited by pioglitazone. When islets were continuously perifused with 5 mM glucose, short-term pretreatment with pioglitazone caused approximately 2-fold increase in insulin secretion after drug withdrawal. Pioglitazone pretreatment of diabetic islets restored their glucose sensitivity. Examination of cytosolic free Ca²⁺ concentration ([Ca²⁺]_i) in non-diabetic islets revealed slight Ca²⁺ transient by pioglitazone at 3 mM glucose with no significant changes at high glucose. Our data suggest that short-term pretreatment with pioglitazone primes both healthy and diabetic human islets for enhanced glucose-sensitive insulin secretion.

Revue / Journal Title

Biochemical and biophysical research communications   ISSN 0006-291X   CODEN BBRCA9 

Source / Source

2006, vol. 351, n^o3, pp. 750-755 [6 page(s) (article)]

Langue / Language

Anglais

Editeur / Publisher

Elsevier, San Diego, CA, ETATS-UNIS  (1959) (Revue)

Mots-clés d'auteur / Author Keywords

Pioglitazone ; Peroxisome proliferator-activated receptor (PPAR) ; Glucose sensitivity ; Insulin secretion ; Cytosolic free Ca2+ concentration ([Ca2+]i) ; Human islets ; Diabetes ;

Localisation / Location

INIST-CNRS, Cote INIST : 8252, 35400015891535.0290